希伯纳斯瓦克:在慢性乙型肝炎的背景下开发和应用
Julio C Aguilar1, Sheikh Mf Akbar2, Mamun Al-Mahtab3
1Department of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
Euroasian journal of hepato-gastroenterology
|January 13, 2025
概括
开发治疗性B型慢性肝炎 (CHB) 疫苗是一种具有成本效益的策略,特别适用于低收入国家. 本综述检查了CHB治疗变量和HeberNasvac疫苗.
科学领域:
- 免疫学 免疫学 免疫学
- 肝病学 肝病学是一种肝病学.
- 疫苗学 疫苗学 疫苗学
背景情况:
- 慢性乙型肝炎 (CHB) 影响2.21亿人,主要在低收入和中等收入国家.
- 免疫系统对于控制乙型肝炎病毒 (HBV) 感染和实现自发或治疗诱导的清除至关重要.
- 治疗性疫苗为CHB管理提供了一个有希望的,具有成本效益的方法.
研究的目的:
- 系统地审查CHB治疗的安全性,疗效和有效性.
- 分析治疗性疫苗的潜力和挑战,使用HeberNasvac作为案例研究.
- 确定治疗性HBV疫苗的研究,开发,注册和实施的障碍.
主要方法:
- 对CHB治疗的系统文献综述.
- 对HeberNasvac的开发和应用数据的分析.
- 评估当前的研究,监管和实施挑战.
主要成果:
- 治疗性疫苗是CHB的合理和经济有效的策略.
- 希伯纳斯瓦克的经验为治疗疫苗开发的实用性提供了洞察力.
- 在研发,监管批准和大规模部署方面仍然存在重大挑战.
结论:
- 治疗性疫苗,如HeberNasvac,对于治疗慢性乙型肝炎有很大的潜力.
- 解决研究,开发和实施障碍对于广泛获取至关重要.
- 需要进一步的投资和战略规划来克服现有的障碍.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Chronic Pancreatitis I: Introduction
Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...


